Patents Assigned to Hadasit Medical Research Services & Development
Limited
-
Patent number: 8962891Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.Type: GrantFiled: November 9, 2008Date of Patent: February 24, 2015Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.Inventors: Arie Dagan, Shimon Slavin, Shimon Gatt, Jeremy Zahavi
-
Publication number: 20150037404Abstract: A method for lubricating a joint of a mammal by administering into a cavity of the joint a composition of liposomes that are multilamellar vesicles (MLV) dispersed in a fluid medium, the liposomes having a mean diameter of between about 0.8 ?m to about 10 ?m and including membranes of at least one glycerophospholipid (GPL) having two C12-C16 hydrocarbon chains which are the same or different. These membranes have a phase transition temperature in which solid ordered (SO) to liquid disordered (LD) phase transition occurs, the phase transition temperature being at a temperature of about 20° C. to about 39° C. and being lower than the temperature of the joint.Type: ApplicationFiled: October 22, 2014Publication date: February 5, 2015Applicants: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Yechezkel BARENHOLZ, Dorit NITZAN, Izhak ETSION, Avi SCHROEDER, Grigory HALPERIN, Sarit SIVAN
-
Patent number: 8940537Abstract: The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasal™ medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.Type: GrantFiled: January 25, 2012Date of Patent: January 27, 2015Assignee: Hadasit Medical Research Services & Development LimitedInventors: Benjamin Reubinoff, Debora Steiner
-
Patent number: 8895054Abstract: The present invention concerns methods of joint lubrication and/or prevention of cartilage wear making use of liposomes having membranes with at least one phospholipid (PL) of the group consisting of a glycerophospholipid (GPL) having two, being the same or different, C12-C16 hydrocarbon chain and a sphingolipid (SPL) having a C12-C15 hydrocarbon chain, the one or more membranes having a phase transition temperature in which solid ordered (SO) to liquid disordered (LD) phase transition occurs, the phase transition temperature being within a temperature of about 20° C. to about 39° C. for lubrication of joints.Type: GrantFiled: March 26, 2009Date of Patent: November 25, 2014Assignees: Technion Research and Development Foundation Ltd., Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of JerusalemInventors: Yechezkel Barenholz, Dorit Nitzan, Izhak Etsion, Avi Schroeder, Grigory Halperin, Sarit Sivan
-
Patent number: 8735149Abstract: Provided is a method for directing differentiation of neural progenitors with a caudal and ventral specification into motor neurons including culturing neural progenitors in a culturing medium including a basic medium supplemented by at least one inhibitor of the Notch signaling pathway whereby the neural progenitors differentiate into postmitotic motor neurons. The resulting motor neurons may be used for drug development, as carriers, e.g. for gene therapy of protein delivery as well as for transplantation for the purpose of treating a motor neuron disease.Type: GrantFiled: April 5, 2009Date of Patent: May 27, 2014Assignee: Hadasit Medical Research Services & Development LimitedInventors: Benjamin Reubinoff, Etti Ben Shushan, Michal Aharonowiz
-
Publication number: 20140128836Abstract: Provided is a device for iontophoretic delivery of a drug to or into a tissue, including an arrangement that prevents operation of the device at a current density that is higher than a predetermined value, the arrangement including first means responsive to a first data item, indicative of the surface area through which the current is to pass, as to set the maximal current allowed at the surface area indicated by the data item. Also provided is a method for iontophorectivally administering drug to or into a tissue, including determining a maximal allowed level of current density and preventing application of current density above the maximal allowed level.Type: ApplicationFiled: January 15, 2014Publication date: May 8, 2014Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventors: Abraham J. DOMB, Joseph FRUCHT-PERY, Mervyn SHAPIRO
-
Patent number: 8666486Abstract: The present invention provides a device for iontophoretic delivery of a drug to on into a tissue, comprising an arrangement that prevents operation of the device at a current density that is higher than a predetermined value, the arrangement including first means responsive to a first data item, indicative of the surface area through which the current is to pass, as to set the maximal current allowed at the surface area indicated by the data item. The present invention also provides a method for iontophorectivally administering drug to or into a tissue, comprising determination of a maximal allowed level of current density and preventing application of current density above the maximal allowed level.Type: GrantFiled: March 3, 2005Date of Patent: March 4, 2014Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of JerusalemInventors: Abraham J. Domb, Joseph Frucht-Pery, Mervyn Shapiro
-
Publication number: 20130331333Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.Type: ApplicationFiled: December 29, 2011Publication date: December 12, 2013Applicant: Hadasit Medical Research Services and Development LimitedInventor: Rachel Bar-Shavit
-
Patent number: 8597947Abstract: The present application discloses methods expanding SCs in an undifferentiated state, the methods comprising incubating undifferentiated SCs in suspension within a culture system comprising basic medium and knockout serum replacement (KOSR). The methods may also be applicable for selective spontaneous or directed differentiation of SCs into a selected population of somatic cells from a culture system of SCs in suspension, the method further comprising incubating said undifferentiated SCs in culture system that support respectively, spontaneous or directed differentiation of SCs into the selected population of somatic cells. The present application also discloses a culture system for expansion of stem cells (SCs) comprising a suspension of undifferentiated stem cells within basic medium and knockout serum replacement (KOSR). The methods and culture system of the invention may be used for large scale production of differentiated cells.Type: GrantFiled: April 2, 2007Date of Patent: December 3, 2013Assignee: Hadasit Medical Research Services & Development LimitedInventor: Benjamin Reubinoff
-
Publication number: 20130280218Abstract: Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III ?-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells.Type: ApplicationFiled: September 27, 2011Publication date: October 24, 2013Applicant: Hadasit Medical Research Services & Development LimitedInventors: Sharona Cohen Evenram, Benjamin Reubinoff
-
Patent number: 8535645Abstract: A particle including at least one aliphatic polymer having anti-microbially active quaternary ammonium groups chemically bound thereto, is provided. The particle may be used to inhibit populations of microorganisms and biofilms. Also provided are methods for the preparation of such particles and uses thereof for the inhibition of microorganisms.Type: GrantFiled: January 1, 2006Date of Patent: September 17, 2013Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of JerusalemInventors: Abraham J. Domb, Ervin Weiss, Nurit Beyth, Ira Farber, Michael Perez Davidi
-
Publication number: 20120122209Abstract: The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasal™ medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.Type: ApplicationFiled: January 25, 2012Publication date: May 17, 2012Applicant: Hadasit Medical Research Services & Development LimitedInventors: Benjamin Reubinoff, Debora Steiner
-
Publication number: 20120088311Abstract: The present invention is based on the finding that antibodies raised against a fragment of PAR1-released peptide may be used to detect in a bodily fluid sample from a subject a marker associated with cancer state, if said subject has cancer.Type: ApplicationFiled: February 5, 2009Publication date: April 12, 2012Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventor: Rachel Bar-Shavit
-
Publication number: 20110293519Abstract: Provided is radiolabeled ammonium salts and uses thereof as myocardial perfusion agents in molecular imaging.Type: ApplicationFiled: May 26, 2011Publication date: December 1, 2011Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventors: Eyal MISHANI, Ohad ILOVICH, Hana BILLAUER, Sharon DOTAN, Haim DANENBERG, Moshe BOCHER, Galith ABOURBEH, Nanette FREEDMAN
-
Publication number: 20110262346Abstract: The present invention provides a reactor and a process for producing spin enriched hydrogen and/or deuterium gas.Type: ApplicationFiled: April 14, 2011Publication date: October 27, 2011Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventors: Rachel KATZ-BRULL, Moshe GOMORI, Claudia M. BARZILAY, Ayelet GAMLIEL
-
Publication number: 20110236438Abstract: A method for treating a disease comprising administering to a mammal in need thereof an effective dosage of an extract of a plant of the genus Hoodia, wherein the disease is selected from the group consisting of immune-mediated disorders, immune-associated disorders, inflammatory diseases, coronary disease, insulin resistance and liver-related diseases. In a preferred embodiment, the Hoodia is Hoodia parviflora. Also disclosed is a pharmaceutical composition for treating the above diseases comprising an effective dosage of an extract of a plant of the genus Hoodia.Type: ApplicationFiled: December 6, 2009Publication date: September 29, 2011Applicants: Hadasit Medical Research Services & Development Limited, Desert Labs Agriculture Cooperative Association LtInventors: Refael Aharon, Yaron Ilan
-
Publication number: 20110177594Abstract: Provided are systems and methods for providing human cell cultures. Further provided are cultures of feeder cells for use in stem cell technology, as well as cultures, culture systems and methods for maintenance and propagating of stem cells in an undifferentiated state as well as for the development of somatic cells cultures from stem cells, the somatic cell cultures being free of extraembryonic cells.Type: ApplicationFiled: January 13, 2011Publication date: July 21, 2011Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventors: Etti Ben SHUSHAN, Shelly TANNENBAUM, Pavel ITSYKSON, Eyal BANIN, Benjamin REUBINOFF
-
Publication number: 20110091927Abstract: The present invention provides a method for directing differentiation of neural progenitors with a caudal and ventral specification into motor neurons comprising culturing neural progenitors in a culturing medium comprising a basic medium supplemented by at least one inhibitor of the Notch signaling pathway whereby said neural progenitors differentiate into postmitotic motor neurons. The resulting motor neurons may be used for drug development, as carriers, e.g. for gene therapy of protein delivery as well as for transplantation for the purpose of treating a motor neuron disease.Type: ApplicationFiled: April 5, 2009Publication date: April 21, 2011Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventors: Benjamin Reubinoff, Etti Ben Shushan, Michal Aharonowiz
-
Publication number: 20110034345Abstract: The present disclosure provides methods for diagnosing a maculopathy. Specifically, the methods are based on determination of a level of at least one biological marker of a maculopathy in a bodily fluid sample of an individual (e.g. blood sample) and comparing the level of the assayed biological marker with the level of prior determined cut off standards. The level of the biological marker provides information regarding the state of the individual, such as whether the individual has the assayed maculopathy, is predisposed to develop said maculopathy, is responsive to treatment, and others.Type: ApplicationFiled: March 13, 2008Publication date: February 10, 2011Applicant: Hadasit Medical Research Services & Development LimitedInventors: Itay Chowers, Avraham Weiss, Michal Lederman
-
Publication number: 20110027351Abstract: Provided is the use of an amphipathic weak base having defined characteristics for the preparation of a pharmaceutical formulation for the treatment or prevention of neurodegenerative conditions. The amphipathic weak base can be encapsulated in a liposome. Also provided are pharmaceutical formulations and methods of use thereof for the treatment or prevention of neurodegenerative conditions. A specific and amphipathic weak base is tempamine (TMN). Further, tempamine can be loaded in sterically stabilized liposomes (SSL-TMN).Type: ApplicationFiled: October 13, 2010Publication date: February 3, 2011Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITEDInventors: Yechezkel BARENHOLZ, Haim OVADIA, Pablo KIZELSZTEIN